What is the purpose of this 8-K filing?

This 8-K filing serves to formally announce Bristol-Myers Squibb's (BMY) intention to make a Net Sales Payment under a Contingent Value Rights (CVR) agreement stemming from the acquisition of Celgene Corporation. It details the amount and timeline for this specific payment.

Who is eligible to receive this payment?

Only holders of the specific contingent value rights issued under the CVR Agreement (related to Celgene's Abraxane® and pipeline products) who are of record as of March 19, 2020, will receive a pro rata portion of the Net Sales Payment.

What is the total amount of the payment and the expected amount per CVR?

The total Net Sales Payment is $6,399,550, which equates to approximately $0.1479 per contingent value right. This payment will be distributed by the Trustee on or before March 20, 2020.

Does this payment affect the value of BMY stock?

This specific payment relates to contingent value rights that were issued as part of the Celgene acquisition. While it represents a fulfillment of an obligation, the amount is relatively small in the context of Bristol-Myers Squibb's overall market capitalization and is not expected to have a material impact on the company's stock price.

BRISTOL MYERS SQUIBB CO 8-K SEC Disclosure

Summary

Bristol-Myers Squibb (BMY) has filed an 8-K report detailing a contingent value rights (CVR) payment related to the acquisition of Celgene Corporation. The company announced a Net Sales Payment of approximately $6.4 million will be made to the CVR trustee. This payment is associated with Celgene's pipeline products, specifically Abraxane® and related assets, which were part of the original CVR agreement established in 2010. Investors holding these specific CVRs should note that the payment will be distributed on or before March 20, 2020, to CVR holders of record as of March 19, 2020. The amount per CVR is expected to be approximately $0.1479. This filing provides transparency on the financial obligations stemming from the significant Celgene acquisition and offers a concrete, albeit small, payout to the holders of these specific contingent value rights.

Key Highlights

1BMY will pay approximately $6.4 million as a Net Sales Payment to the CVR trustee.
2This payment is related to contingent value rights (CVRs) tied to Celgene's Abraxane® and pipeline products.
3The CVRs originated from Celgene's prior agreement dated October 15, 2010.
4The Net Sales Payment will be made on or before March 20, 2020.
5CVR holders of record as of March 19, 2020, will receive a pro rata portion of the payment.
6The expected payment per CVR is approximately $0.1479.

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Mar 9, 2020)

Summary

Key Highlights

Frequently Asked Questions